Importantly, we observed that 45% of the stabilized cell lines (our data and CCLE) show both TP53 mutation and homozygous deletion of CDKN2A, while these alterations are described as mutually exclusive in glioblastoma in vivo[28]–[30], [36]. The gene discussed is CDKN2A; the disease is glioblastoma.